Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

(2019) José Alexandre S. Crippa et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System

(2018) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2

(2018) William R. Arnold et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Interactions between cannabidiol and commonly used antiepileptic drugs

(2017) Tyler E. Gaston et al.   EPILEPSIA

Labeling Accuracy of Cannabidiol Extracts Sold Online

(2017) Marcel O. Bonn-Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes

(2017) Ryan Vandrey et al.   JOURNAL OF ANALYTICAL TOXICOLOGY

Medical Cannabinoids in Children and Adolescents: A Systematic Review

(2017) Shane Shucheng Wong et al.   PEDIATRICS

Cannabidiol: State of the art and new challenges for therapeutic applications

(2017) Simona Pisanti et al.   PHARMACOLOGY & THERAPEUTICS

Demographic trends among older cannabis users in the United States, 2006-13

(2016) Benjamin H. Han et al.   ADDICTION

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

(2016) Orrin Devinsky et al.   LANCET NEUROLOGY

A systematic review of physical illness, functional disability, and suicidal behaviour among older adults

(2015) Madeleine Mellqvist Fässberg et al.   AGING & MENTAL HEALTH

Clinical Association Between Pharmacogenomics and Adverse Drug Reactions

(2015) Zhi-Wei Zhou et al.   DRUGS

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

Cannabinoids for Medical Use

(2015) Penny F. Whiting et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Molecular Targets of Cannabidiol in Neurological Disorders

(2015) Clementino Ibeas Bih et al.   Neurotherapeutics

Drug-Induced Megaloblastic Anemia

(2015) Charles S. Hesdorffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Major depressive disorder, suicidal behaviour, bipolar disorder, and generalised anxiety disorder among emerging adults with and without chronic health conditions

(2015) M. A. Ferro   Epidemiology and Psychiatric Sciences

Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol

(2014) Satoshi Yamaori et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa

(2014) Alexandre Schier et al.   CNS & Neurological Disorders-Drug Targets

Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing

(2013) SL Van Driest et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19

(2013) Rongrong Jiang et al.   Drug Metabolism and Pharmacokinetics

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

(2013) Colin Stott et al.   SpringerPlus

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Identification of Recent Cannabis Use: Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics following Controlled Smoked Cannabis Administration

(2011) D. M. Schwope et al.   CLINICAL CHEMISTRY

Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6

(2011) S. Yamaori et al.   DRUG METABOLISM AND DISPOSITION

Comparison in the In Vitro Inhibitory Effects of Major Phytocannabinoids and Polycyclic Aromatic Hydrocarbons Contained in Marijuana Smoke on Cytochrome P450 2C9 Activity

(2011) Satoshi Yamaori et al.   Drug Metabolism and Pharmacokinetics

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety

(2011) Satoshi Yamaori et al.   LIFE SCIENCES

Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes

(2010) Satoshi Yamaori et al.   BIOCHEMICAL PHARMACOLOGY

Plasma Cannabinoid Pharmacokinetics following Controlled Oral  9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration

(2010) E. L. Karschner et al.   CLINICAL CHEMISTRY

Drug-induced immune hemolytic anemia

(2009) Abdulgabar Salama   Expert Opinion On Drug Safety

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain

(2009) Jeremy R. Johnson et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

Novel cannabinoid receptors

(2007) A J Brown   BRITISH JOURNAL OF PHARMACOLOGY